{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:02:29Z","timestamp":1779692549361,"version":"3.53.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The predictive value of hematological parameters for pathologic response to neoadjuvant immunochemotherapy (NICT) in locally advanced gastric cancer (LAGC) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study consecutively enrolled 246 LAGC patients who received NICT followed by radical gastrectomy at The First Hospital of Lanzhou University (2021-2024). Based on postoperative pathology, patients were classified into major pathologic response (MPR, tumor regression grade [TRG] 1a\/1b, residual tumor \u226410%) and incomplete pathologic response (IPR, TRG 2\/3, residual tumor &amp;gt;10%) groups. Hematological parameters pre- and post-treatment were analyzed. Logistic regression and receiver operating characteristic (ROC) analyses were employed (statistical significance: p&amp;lt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multivariate analysis identified pre-treatment neutrophil count (Neutrophil_pre) (adjusted odds ratio [OR]: 0.83, 95% CI: 0.70\u20130.99, P\u00a0=\u00a00.033) and post-treatment albumin (ALB_post) (adjusted OR: 0.92, 95% CI: 0.85\u20131.00, P\u00a0=\u00a00.042) as independent protective factors for MPR, while post-treatment platelet count (PLT_post) was an independent risk factor (adjusted OR: 1.01, 95% CI: 1.00\u20131.01, P\u00a0=\u00a00.014). These associations were absent in a chemotherapy-alone control cohort (n=147). ROC analysis determined the optimal pre-treatment neutrophil cutoff at 3.39\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Subgroup analysis showed that among patients with pre-treatment neutrophils &amp;lt;3.39\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L, those receiving 4 (vs. 2-3) cycles of neoadjuvant therapy had significantly higher MPR (35.7% vs. 16.9%, P\u00a0=\u00a00.039) and pathologic complete response (pCR) rates (32.1% vs. 9.1%, P\u00a0=\u00a00.011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-treatment neutrophil count, post-treatment platelet count, and post-treatment albumin level are independent predictors of pathologic response to NICT in LAGC. Patients with low pre-treatment neutrophil levels may benefit from extended (4-cycle) neoadjuvant immunochemotherapy with higher pathologic response rates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1795481","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:03:50Z","timestamp":1779689030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinglong","family":"Lu","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Du","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Ma","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixi","family":"An","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjiang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Hospital of Lanzhou University","place":["Lanzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101599","article-title":"Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review","volume":"38","author":"Sugawara","year":"2021","journal-title":"Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041054","article-title":"The new era of immunotherapy in gastric cancer","volume":"14","author":"Takei","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12957-025-03710-8","article-title":"Evaluating the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced gastric cancer undergoing radical gastrectomy: a retrospective study","volume":"23","author":"Li","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00262-025-04153-6","article-title":"The efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for locally advanced gastric cancer: a single-center, real-world clinical study","volume":"74","author":"Pan","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: Current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411849","article-title":"Neoadjuvant immunotherapy: A promising new standard of care","volume":"24","author":"Boydell","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.683110","article-title":"Benchmarks for the assessment of novel cardiovascular biomarkers","volume":"115","author":"Morrow","year":"2007","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4869-5","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis","volume":"23","author":"Yodying","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1497004","article-title":"Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180810","article-title":"Neutrophil diversity in inflammation and cancer","volume":"14","author":"Carnevale","year":"2023","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12876-025-03920-0","article-title":"Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer","volume":"25","author":"Qi","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189350","article-title":"Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: Update and new challenges","volume":"1880","author":"Sun","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.25691","article-title":"Prognostic value of systemic immune-inflammation index in patients with gastric cancer: a meta-analysis","volume":"12","author":"Yang","year":"2017","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4251\/wjgo.v12.i1.37","article-title":"Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines","volume":"12","author":"Wang","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00345-015-1667-4","article-title":"Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy","volume":"34","author":"Zargar-Shoshtari","year":"2016","journal-title":"World J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002190","article-title":"Identifying the optimal number of neoadjuvant chemotherapy cycles in patients with muscle invasive bladder cancer","volume":"207","author":"D'Andrea","year":"2022","journal-title":"J Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-439","article-title":"Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers","volume":"11","author":"Deng","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00292-021-01023-7","article-title":"The updated WHO classification of digestive system tumours-gastric adenocarcinoma and dysplasia","volume":"43","author":"Kushima","year":"2022","journal-title":"Pathologe"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.11660","article-title":"Histomorphologic regression grading in gastric carcinoma after neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.05.005","article-title":"Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies","volume":"58","author":"Mei","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s153290","article-title":"Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis","volume":"11","author":"Sacdalan","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12929-017-0341-0","article-title":"Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets","volume":"24","author":"Tsai","year":"2017","journal-title":"J BioMed Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-025-01731-0","article-title":"Target neutrophil heterogeneity and plasticity in cancer","volume":"18","author":"Feng","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70063","article-title":"Neutrophil heterogeneity and plasticity: unveiling the multifaceted roles in health and disease","volume":"6","author":"He","year":"2025","journal-title":"MedComm"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.325","article-title":"The double-edged role of neutrophil heterogeneity in inflammatory diseases and cancers","volume":"4","author":"Zhou","year":"2023","journal-title":"MedComm"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.4_suppl.472","article-title":"Unraveling the role of interferon-stimulated neutrophils: A promising biomarker for immunotherapy efficacy and prognosis in gastric adenocarcinoma","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","article-title":"Interferon-stimulated neutrophils as a predictor of immunotherapy response","volume":"42","author":"Benguigui","year":"2024","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422717","article-title":"Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study","volume":"15","author":"Zhai","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1405704","article-title":"Risk factor analysis and nomogram construction of postoperative complications for patients with locally advanced gastric cancer who received neoadjuvant immunotherapy and chemotherapy","volume":"11","author":"Cui","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.e11012","article-title":"Pathologic complete response rates following neoadjuvant chemotherapy in the treatment of locally advanced breast cancer","volume":"29","author":"Prabhudesai","year":"2011","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131787","article-title":"Lighting up the fire in the microenvironment of cold tumors: A major challenge to improve cancer immunotherapy","volume":"12","author":"Benoit","year":"2023","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6054","article-title":"The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis","volume":"13","author":"Zhang","year":"2017","journal-title":"Oncol Lett"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2020.1810653","article-title":"Prognostic significance of thrombocytosis in lung cancer: a systematic review and meta-analysis","volume":"32","author":"Ma","year":"2021","journal-title":"Platelets"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111350","article-title":"Antigen B from Echinococcus granulosus regulates macrophage phagocytosis by controlling TLR4 endocytosis in immune thrombocytopenia","volume":"406","author":"Zhang","year":"2025","journal-title":"Chem Biol Interact"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/moh.0000000000000782","article-title":"The immunology of PF4 polyanion interactions","volume":"30","author":"Ngo","year":"2023","journal-title":"Curr Opin Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"154157","DOI":"10.1016\/j.cyto.2017.09.013","article-title":"Platelet-derived chemokines in inflammation and atherosclerosis","volume":"122","author":"Bakogiannis","year":"2019","journal-title":"Cytokine"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110441","article-title":"Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis","volume":"10","author":"Plantureux","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2018.1453059","article-title":"The pro-inflammatory role of platelets in cancer","volume":"29","author":"Olsson","year":"2018","journal-title":"Platelets"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01805","article-title":"Platelets, thrombo-inflammation, and cancer: Collaborating with the enemy","volume":"10","author":"Palacios-Acedo","year":"2019","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.734735","article-title":"Hypoalbuminaemia as a prognostic biomarker of first-line treatment resistance in metastatic non-small cell lung cancer","volume":"8","author":"Stares","year":"2021","journal-title":"Front Nutr"},{"key":"B53","doi-asserted-by":"publisher","first-page":"11244","DOI":"10.21203\/rs.3.rs-3943202\/v1","article-title":"Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma","volume":"14","author":"Leek","year":"2024","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1795481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:03:51Z","timestamp":1779689031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1795481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1795481"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1795481","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1795481"}}